The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia: A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks

Psychopharmacology

Volumn 170, Issue 4, 2003, Pages 423-428

  Rodenbeck, A ^a   Cohrs, S ^a   Jordan, W ^a   Huether, G ^a   Ruther E ^a   Hajak, G ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antidepressant; Cortisol; Insomnia; Sedative

Indexed keywords

ANTIDEPRESSANT AGENT; DOXEPIN; HYDROCORTISONE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; MALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SEDATION; SLEEP DISORDER; SLEEP TIME; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOXEPIN; FEMALE; HUMANS; HYDROCORTISONE; MALE; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0346973887     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1565-0     Document Type: Article

References (56)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
2. American Sleep Disorders Association (1990) The international classification of sleep disorders. American Sleep Disorders Association, Rochester, MN
3. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ (2001) Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155:323-326
4. Balter MB, Uhlenhuth EH (1992) New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 53:34-39
5. Bhagwagar Z, Hafizi S, Cowen PJ (2002a) Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 163:118-120
6. Bhagwagar Z, Whale R, Cowen PJ (2002b) State and trait abnormalities in serotonin function in major depression. Br J Psychiatry 180:24-28
7. Berlin I, Warot D, Legout V, Guilleminault S, Schollnhammer G, Puech AJ (1998) Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 63:428-436
8. Bixler EO, Vgontzas AN, Lin HM, Vela-Bueno A, Kales A (2002) Insomnia in central Pennsylvania. J Psychosom Res 53:589-592
9. Duncan WCJ (1996) Circadian rhythms and the pharmacology of affective disorders. Pharmacol Ther 71:253-312
10. Feuillade P, Pringuey D, Belugou JL, Robert P, Darcourt G (1992) Trimipramine: acute and lasting effects on sleep in healthy and major depressive subjects. J Affect Disord 24:135-145
11. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter EZ (1989) The effect of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 68:632-637
12. Götze U, Tölle R (1988) Circadian rhythm of free urinary cortisol, temperature and heart rate in endogenous depression and under antidepressant therapy. Neuropsychobiology 18:175-184
13. Hajak G, Rodenbeck A, Adler L, Huether G, Bandelow B, Herrendorf G, Staedt J, Rüther E (1996) Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 29:187-192
14. Hajak G, Rodenbeck A, Ehrenthal HD, Leonard S, Wedekind D, Sengos G, Zhou D, Huether G (1997) No evidence for a physiological coupling between melatonin and glucocorticoids. Psychopharmacology 133:313-322
15. Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E (2001a) Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62:453-463
16. Hajak G on behalf of the SINE study group (2001b) Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 251:49-56
17. Harmer CJ, Bhagwagar Z, Shelley N, Cowen PJ (2003) Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 167:112-114
18. Hohagen F, Montero RF, Weiss E, Lis S, Schönbrunn E, Dressing H, Riemann D, Berger M (1994) Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 244:65-72
19. Holl WR, Fehm HL, Voigt KH, Steiner K, Teller W (1986) Acute effects of desipramine and clomipramine on pituitary-adrenal axis in man. Horm Metab Res 18:134-137
20. Inder WJ, Prickett TCR, Mulder RT, Donald RA, Joyce PR (2001) Reduction of basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology 156:73-78
21. Jarrett DB, Miewals JM, Kupfer DJ (1988) Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine. Biol Psychiatry 24:541-554
22. Jarrett DB, Pollock B, Miewald JM, Kupfer DJ (1991) Acute effect of intravenous clomipramine upon sleep-related hormone secretion in depressed outpatients and healthy subjects. Biol Psychiatry 29:3-14
23. Kapitany T, Schindl M, Schindler SD, Hesselmann B, Fureder T, Barnas C, Sieghart W, Kasper S (1999) The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88:75-88
24. Laakmann G, Wittmann M, Gugath M, Mueller OA, Treusch J, Wahlster U, Stalla GK (1984) Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology 84:66-70
25. Laakmann G, Schoen HW, Blaschke D, Wittmann M (1985) Dose-dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects. Psychoneuroendocrinology 10:83-93
26. Laakmann G, Schule C, Baghai T, Waldvogel E (1999) Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 24:769-784
27. Linkowski P, Mendlewicz J, Kerkhofs M, Leclercq R, Goldstein J, Brasseur M, Copinschi G, van Cauter E (1987) 24-hour profiles of adrenocroticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocr Metab 64:141-152
28. Lisansky J, Fava GA, Zielezny MA, Morphy MA, Kellner R (1987) Nocturnal prolactin and cortisol secretion and recovery from melancholia. Psychoneuroendocrinology 12:303-311
29. Madjirova NP, Tashev TG, Delchev NN, Bakalova RG (1995) Interrelationship between cortisol levels in plasma and the circadian rhythm of temperature, pulse and blood pressure in depressed patients with good and disturbed sleep. Int J Psychophysiol 20:145-154
30. Monteleone P (1991) Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology 5:61-64
31. Nowell PD, Reynolds CF, Buysse DJ, Dew MA, Kupfer DJ (1999) Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 60:89-95
32. Ohayon MM, Caulet M, Piest RG, Guilleminault C (1998) Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 51:273-283
33. Piacentini MF, Meeusen R, Buyse L, De-Schutter G, Kempenaers F, Van-Nijvel J, De-Meirleir K (2002) No effect of a noradrenergic reuptake inhibitor on performance in trained cyclists. Med Sci Sports Exerc 34:1189-1193
34. Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. U.S. Government Printing Office, Washington
35. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Rüther E, Wiegand MH, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Mayer G, Berger M (2002) Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 35:165-174
36. Rodenbeck A, Hajak G (2001) Neuroendocrine dysregulation in primary insomnia. Rev Neurol (Paris) 157:s57-s61
37. Rodenbeck A, Huether G, Rüther E, Hajak G (2002) Interactions between evening and nocturnal cortisol secretion and sleep parameters in patients with severe chronic primary insomnia. Neurosci Lett 324:159-163
38. Schlosser R, Wetzel H, Dorr H, Rossbach W, Hiemke C, Benkert O (2000) Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 25:377-388
39. Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14:253-263
40. Simen S, Rodenbeck A, Schlaf G, Müller-Popkes K, Hajak G (1996) Sleep complaints and hypnotic use by the elderly -results of a representative survey in West Germany. Wien Med Wochenschr 146:306-309
41. Simon GE, VonKorff M (1997) Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 154:1417-1423
42. Sonntag A, Rother B, Guldner J, Yassouridis A, Holsboer F, Steiger A (1996) Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 4:1-13
43. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J (1995) Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 18:470-477
44. Steiger A, von Bardeleben U, Herth T, Holsboer F (1989) Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before and after recovery. J Affect Disord 16:189-195
45. Steiger A, von Bardeleben U, Guldner J, Lauer C, Rother B, Holsboer F (1993) The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry 17:125-137
46. Torpy DJ, Grice JE, Hockings GI, Crosbie GV, Walters MM, Jackson RV (1995) The effect of desipramine on basal and naloxone-stimulated cortisol secretion in human: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion. J Clin Endocr Metab 80:802-806
47. Van Cauter E, Leproult R, Kupfer DJ (1996) Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 81:2468-2473
48. Vgontzas AN, Tsigos C, Bixler EO, Stratakis CA, Zachman K, Kales A, Vela-Bueno A, Chrousos GP (1998) Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res 45:21-31
49. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP (2001) Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 86:3787-3794
50. Walsh AE, Hockney RA, Campling G, Cowen PJ (1993) Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Biol Psychiatry 33:115-119
51. Walsh JK, Schweitzer PK (1999) Ten-year trends in the pharmacological treatment of insomnia. Am J Psychiatry 22:371-375
52. Wiegand M, Berger M (1989) Action of trimipramine on sleep and pituitary hormone secretion. Drugs 38[Suppl 1]:35-50
53. Wilkins JN, Spar JE, Carlson HE (1989) Desipramine increases circulating growth hormone in elderly patients: a pilot study. Psychoneuroendocrinology 14:195-202
54. Wittchen HU, Krause P, Hofler M, Pittrow D, Winter S, Spiegel B, Hajak G, Riemann D, Steiger A, Pfister H (2001) NISAS-2000. The nationwide insomnia screening and awareness study. Prevalence and interventions in primary care. Fortschr Med Orig 119:9-19
55. World Health Organization (1991) Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and guidelines. In: International classification of diseases, 10th revn. World Health Organization, Geneva
56. Wysowski DK, Baum C (1991) Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 151:1779-1783